Annual CFF
-$397.88 M
-$387.40 M-3697.65%
31 December 2023
Summary:
Supernus Pharmaceuticals annual cash flow from financing activities is currently -$397.88 million, with the most recent change of -$387.40 million (-3697.65%) on 31 December 2023. During the last 3 years, it has fallen by -$267.46 million (-205.08%). SUPN annual CFF is now -205.70% below its all-time high of $376.44 million, reached on 31 December 2018.SUPN Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$3.08 M
+$1.42 M+85.46%
30 September 2024
Summary:
Supernus Pharmaceuticals quarterly cash flow from financing activities is currently $3.08 million, with the most recent change of +$1.42 million (+85.46%) on 30 September 2024. Over the past year, it has increased by +$1.98 million (+181.59%). SUPN quarterly CFF is now -99.16% below its all-time high of $367.71 million, reached on 31 March 2018.SUPN Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$7.39 M
+$3.31 M+80.81%
30 September 2024
Summary:
Supernus Pharmaceuticals TTM cash flow from financing activities is currently $7.39 million, with the most recent change of +$3.31 million (+80.81%) on 30 September 2024. Over the past year, it has increased by +$405.27 million (+101.86%). SUPN TTM CFF is now -98.04% below its all-time high of $377.88 million, reached on 30 June 2018.SUPN TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SUPN Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | +181.6% | +101.9% |
| 3 y3 years | -205.1% | +102.3% | +105.7% |
| 5 y5 years | -10000.0% | +143.5% | +88.3% |
SUPN Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -3697.7% | at low | -96.2% | +100.6% | -91.9% | +101.5% |
| 5 y | 5 years | <-9999.0% | at low | -96.2% | +100.6% | -91.9% | +101.5% |
| alltime | all time | -205.7% | at low | -99.2% | +100.6% | -98.0% | +101.5% |
Supernus Pharmaceuticals Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $3.08 M(+85.5%) | $7.39 M(+80.8%) |
| June 2024 | - | $1.66 M(+5.6%) | $4.09 M(-100.9%) |
| Mar 2024 | - | $1.57 M(+43.8%) | -$476.48 M(+19.8%) |
| Dec 2023 | -$397.88 M(+3697.7%) | $1.09 M(-574.8%) | -$397.88 M(+0.4%) |
| Sept 2023 | - | -$230.00 K(-100.0%) | -$396.14 M(+1.7%) |
| June 2023 | - | -$478.92 M(-697.3%) | -$389.46 M(-524.6%) |
| Mar 2023 | - | $80.17 M(+2734.0%) | $91.73 M(-975.5%) |
| Dec 2022 | -$10.48 M(-92.0%) | $2.83 M(-56.2%) | -$10.48 M(-93.0%) |
| Sept 2022 | - | $6.46 M(+184.0%) | -$150.05 M(-3.3%) |
| June 2022 | - | $2.27 M(-110.3%) | -$155.18 M(+0.3%) |
| Mar 2022 | - | -$22.03 M(-83.9%) | -$154.70 M(+18.6%) |
| Dec 2021 | -$130.42 M(-3764.5%) | -$136.74 M(<-9900.0%) | -$130.42 M(-1489.1%) |
| Sept 2021 | - | $1.32 M(-51.8%) | $9.39 M(+32.5%) |
| June 2021 | - | $2.75 M(+22.3%) | $7.09 M(+22.7%) |
| Mar 2021 | - | $2.25 M(-26.8%) | $5.77 M(+62.2%) |
| Dec 2020 | $3.56 M(-9.4%) | $3.07 M(-413.5%) | $3.56 M(+103.0%) |
| Sept 2020 | - | -$979.00 K(-168.1%) | $1.75 M(-41.1%) |
| June 2020 | - | $1.44 M(+4390.6%) | $2.97 M(-6.4%) |
| Mar 2020 | - | $32.00 K(-97.5%) | $3.18 M(-19.1%) |
| Dec 2019 | $3.93 M(-99.0%) | $1.26 M(+421.9%) | $3.93 M(+0.3%) |
| Sept 2019 | - | $242.00 K(-85.2%) | $3.92 M(-13.0%) |
| June 2019 | - | $1.64 M(+109.5%) | $4.50 M(-52.7%) |
| Mar 2019 | - | $783.00 K(-37.4%) | $9.51 M(-97.5%) |
| Dec 2018 | $376.44 M(+6526.3%) | $1.25 M(+51.1%) | $376.44 M(+0.0%) |
| Sept 2018 | - | $828.00 K(-87.5%) | $376.36 M(-0.4%) |
| June 2018 | - | $6.65 M(-98.2%) | $377.88 M(+1.4%) |
| Mar 2018 | - | $367.71 M(>+9900.0%) | $372.79 M(+6462.0%) |
| Dec 2017 | $5.68 M | $1.17 M(-50.1%) | $5.68 M(+7.0%) |
| Sept 2017 | - | $2.35 M(+50.4%) | $5.31 M(+64.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2017 | - | $1.56 M(+158.3%) | $3.22 M(+27.2%) |
| Mar 2017 | - | $604.00 K(-24.2%) | $2.53 M(+23.4%) |
| Dec 2016 | $2.05 M(+9.9%) | $797.00 K(+206.5%) | $2.05 M(-0.1%) |
| Sept 2016 | - | $260.00 K(-70.1%) | $2.06 M(+10.9%) |
| June 2016 | - | $871.00 K(+602.4%) | $1.85 M(+0.5%) |
| Mar 2016 | - | $124.00 K(-84.5%) | $1.84 M(-1.2%) |
| Dec 2015 | $1.87 M(-93.9%) | $800.00 K(+1279.3%) | $1.87 M(+36.0%) |
| Sept 2015 | - | $58.00 K(-93.3%) | $1.37 M(-95.6%) |
| June 2015 | - | $862.00 K(+486.4%) | $31.33 M(+2.0%) |
| Mar 2015 | - | $147.00 K(-52.0%) | $30.71 M(+0.5%) |
| Dec 2014 | $30.57 M(-51.3%) | $306.00 K(-99.0%) | $30.57 M(+6.1%) |
| Sept 2014 | - | $30.01 M(>+9900.0%) | $28.81 M(-2457.6%) |
| June 2014 | - | $245.00 K(+4800.0%) | -$1.22 M(-101.9%) |
| Mar 2014 | - | $5000.00(-100.3%) | $63.77 M(+1.6%) |
| Dec 2013 | $62.74 M(-28.6%) | -$1.45 M(+7977.8%) | $62.74 M(-41.1%) |
| Sept 2013 | - | -$18.00 K(-100.0%) | $106.57 M(+2.1%) |
| June 2013 | - | $65.23 M(-6489.0%) | $104.36 M(+18.7%) |
| Mar 2013 | - | -$1.02 M(-102.4%) | $87.95 M(+0.0%) |
| Dec 2012 | $87.92 M(+224.6%) | $42.38 M(-2004.5%) | $87.92 M(+45.5%) |
| Sept 2012 | - | -$2.23 M(-104.6%) | $60.43 M(-1.5%) |
| June 2012 | - | $48.82 M(-4718.9%) | $61.34 M(+356.9%) |
| Mar 2012 | - | -$1.06 M(-107.1%) | $13.43 M(-50.4%) |
| Dec 2011 | $27.09 M(-2969.4%) | $14.89 M(-1230.4%) | $27.09 M(+122.0%) |
| Sept 2011 | - | -$1.32 M(-244.4%) | $12.20 M(-9.7%) |
| June 2011 | - | $912.00 K(-92.8%) | $13.52 M(+7.2%) |
| Mar 2011 | - | $12.61 M | $12.61 M |
| Dec 2010 | -$944.00 K(-122.1%) | - | - |
| Dec 2009 | $4.28 M(-93.4%) | - | - |
| Dec 2008 | $64.46 M(>+9900.0%) | - | - |
| Dec 2007 | $5000.00 | - | - |
FAQ
- What is Supernus Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for Supernus Pharmaceuticals?
- What is Supernus Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Supernus Pharmaceuticals?
- What is Supernus Pharmaceuticals quarterly CFF year-on-year change?
- What is Supernus Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for Supernus Pharmaceuticals?
- What is Supernus Pharmaceuticals TTM CFF year-on-year change?
What is Supernus Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of SUPN is -$397.88 M
What is the all time high annual CFF for Supernus Pharmaceuticals?
Supernus Pharmaceuticals all-time high annual cash flow from financing activities is $376.44 M
What is Supernus Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of SUPN is $3.08 M
What is the all time high quarterly CFF for Supernus Pharmaceuticals?
Supernus Pharmaceuticals all-time high quarterly cash flow from financing activities is $367.71 M
What is Supernus Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, SUPN quarterly cash flow from financing activities has changed by +$1.98 M (+181.59%)
What is Supernus Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of SUPN is $7.39 M
What is the all time high TTM CFF for Supernus Pharmaceuticals?
Supernus Pharmaceuticals all-time high TTM cash flow from financing activities is $377.88 M
What is Supernus Pharmaceuticals TTM CFF year-on-year change?
Over the past year, SUPN TTM cash flow from financing activities has changed by +$405.27 M (+101.86%)